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Janus kinase 3 (JAK3) tyrosine kinase has a central role in the control of lymphopoiesis,
andmutations in JAK3 can lead to either severe combined immunodeficiency or leukemia
and lymphomas. JAK3 associates with the common gamma chain (γc) receptor and
functions in a heteromeric signaling pair with JAK1. In IL-2 signaling JAK1 is the effector
kinase for STAT5 phosphorylation but the precise molecular regulatory mechanisms of
JAK1 and JAK3 and their individual domains are not known. The pseudokinase domain
(JAK homology 2, JH2) of JAK3 is of particular interest as approximately half of clinical
JAK3 mutations cluster into it.
In this study, we investigated the role of JH2s of JAK1 and JAK3 in IL-2R signaling
and show that STAT5 activation requires both JH1 and JH2 of JAK1, while both
JH1 and JH2 in JAK3 are specifically required for the cytokine-induction of cellular
signaling. Characterization of recombinant JAK3 JH2 in thermal shift assay shows an
unstable protein domain, which is strongly stabilized by ATP binding. Unexpectedly,
nucleotide binding to JAK3 JH2 was found to be cation-independent. JAK3 JH2
showed higher nucleotide binding affinity in MANT-ATP and fluorescent polarization
competition assays compared to the other JAK JH2s. Analysis of the functional role of
ATP binding in JAK3 JH2 in cells and in zebrafish showed that disruption of ATP binding
suppresses ligand-independent activation of clinical JAK3 gain-of-function mutations
residing in either JH2 or JH1 but does not inhibit constitutive activation of oncogenic
JAK1. ATP-binding site mutations in JAK3 JH2 do not, however, abrogate normal IL-2
signalingmaking them distinct from JH2 deletion or kinase-deficient JAK3. These findings
underline the importance of JAK3 JH2 for cellular signaling in both ligand-dependent
and in gain-of-function mutation-induced activation. Furthermore, they identify the JH2
ATP-binding site as a key regulatory region for oncogenic JAK3 signaling, and thus a
potential target for therapeutic modulation.
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INTRODUCTION
The family of Janus kinases (JAK1, JAK2, JAK3, and TYK2) are
key mediators of cytokine signaling that regulate hematopoietic
cell development, cellular metabolism and immune responses.
Within the JAK family, JAK3 is unique in its restricted expression
to hematopoietic lineages and specific interaction only with
the common γ chain (γc) cytokine receptor (1). In cytokine
signaling, JAK3 functions in a heterodimeric pair with JAK1,
which binds to the cytokine specific receptor β chains. The
JAK1-JAK3 pair transmit signals emanating from interleukin
(IL)−2, −4, −7, −9, −15, and −21 that regulate development
and activation of lymphoid lineage cells (2). The critical role
of JAK3 in lymphoid cells is highlighted by the phenotypes of
JAK3 activating mutations causing different types of leukemia
and lymphomas (3–5), as well as by JAK3 deficiencies that
cause severe combined immunodeficiency (SCID); a condition
resulting from profound defects in mature T cells and B cells and
innate lymphoid cells including NK cells (6–8).
JAKs share a conserved domain structure consisting of
an N-terminal FERM domain and a Src homology 2 (SH2)-
like domain that comprise the receptor-binding unit, followed
by a pseudokinase domain (JAK homology 2, JH2) and a
tyrosine kinase domain (JH1) (1, 9, 10). Signaling is initiated by
cytokine binding to the extracellular domain of their respective
receptors that induces receptor dimerization/oligomerization or
a conformational shift juxtaposing the JAKs and allowing their
activation through trans-autophosphorylation of the activation
loop tyrosine residues. Following activation, JAKs phosphorylate
tyrosine residues in the receptor chains leading to recruitment
and subsequent phosphorylation of downstream effectors such
as the signal transducers and activators of transcription (STATs)
(1, 2, 10). In IL-2 receptor (IL-2R) signaling, JAK1 has been
shown to play a dominant role in early cytoplasmic activation
events where JAK1 is primarily driving STAT5 phosphorylation
(11), while JAK3 is required for sustained activation during
T-cell proliferation (11, 12). Both functions are dependent on
the catalytic activity of the JH1 domains in JAK1 and JAK3,
respectively. However, several aspects of IL-2R signal regulation
are still elusive, especially with respect to the roles of the
pseudokinase domains.
JAK kinases are constitutively associated with cytokine
receptors and the activity of the JAK–STAT pathway needs to
be tightly regulated at multiple levels to suppress signaling in
the absence of cytokine stimulation and to allow rapid, transient
activation upon stimulation (9, 10). Regulation relies primarily
on control of the JH1 tyrosine kinase activity through intra-
and intermolecular mechanisms (1, 9), and for the former,
the function of JH2 is important, although still somewhat
enigmatic. Genetic studies provide compelling evidence for the
regulatory function of JH2 as disease-causing mutations strongly
cluster in JAK JH2s (13, 14). The best characterized example
is JAK2 where somatic mutations in JH2 (JAK2 V617F and
>30 other mutations) result in constitutively active JAK2 and
are responsible for approximately 80% of myeloproliferative
neoplasms (MPN) and less frequently for different types of
leukaemias including acute lymphoblastic leukemia (ALL),
acute megakaryoblastic leukemia (AMKL), and acute myeloid
leukemia (AML) (5, 14, 15). In JAK3, approximately half of all
clinical mutations localize to JH2 (13, 16).
JAK3 JH2 has two interesting and unique features compared
to the other JAKs: it is the only JH2 harboring both activating
and inactivating clinical mutations, and secondly it is the only
JH2 where the prototypic JH2 gain-of-function mutation (JAK2
V617F, JAK3 homolog M592F) does not cause hyperactivation
(17). Some inhibitory SCID mutations result in truncated
proteins, but several mutations cause amino acid changes
in either the C- and N-lobes of JH2 (e.g., E481G, del482-
596, R582W, G589S, C759R). More recently, several activating
JAK3 JH2 mutations (e.g., M511I, A572V, R657Q, V722I)
have been found in acute myeloid and lymphoblastic leukemia
(AMKL, T-ALL, AML, natural killer cell lymphoma, acute
megakaryoblastic leukemia, T-cell prolymphocytic leukemia,
juvenile myelomonocytic leukemia and natural killer T cell
lymphoma) (3, 4, 18). Although genetic information from
patients provide compelling evidence for the importance of JH2
regulatory function, they do not provide molecular explanations
of the underlying mechanisms of normal or pathogenic JH2
function.
JAK JH2s show significant sequence homology with classical
protein kinases but several conserved functional residues or
motifs are missing or altered. Most importantly, the HRD motif,
including the catalytic base aspartate (D) is replaced by HGN
resulting in a presumably catalytically inactive kinase (hence
“pseudokinase”) (19–21). Structural and biochemical analysis
of JAK1, JAK2 and TYK2 JH2s have shown that despite the
sequence variations, the JH2 domains adopt a typical two lobed
kinase-fold able to bind ATP (22–24). JAK2 and TYK2 JH2
structures have been solved with ATP and they show a non-
canonical binding mode with ATP complexed to only a single
cation instead of the usual two (23, 25). In addition, the canonical
ionic interaction between the β3 lysine (K556 in JAK3 JH2; K72
in the archetypal cAMP-dependent protein kinase PKA) and αC
(E91 in PKA, alanine in JAK JH2s) is replaced by a β3 lysine–
aspartate interaction to the DFG motif (DPG in JAK JH2s)
(19, 23, 25–27).
Early biochemical studies suggested a dual regulatory or
“switch” function for JH2 where the domain is required for
maintaining JAKs inactive in the absence cytokine stimulation,
as well as mediating cytokine-induced signaling (27–31). Recent
structural information from JAK2 (structural model) and TYK2
(crystal structure) provide molecular basis for the JH2 inhibitory
function and show that JH2 interacts with the hinge-region of
JH1 and stabilizes the JH1 in an inactive conformation (27, 32).
Most gain-of-function JAK2 disease mutations localize in this
interface and are predicted to disrupt the JH1–JH2 autoinhibitory
interaction resulting in constitutive activation (27, 28, 33). The
nature of the activating function of JH2 in cytokine signaling and
in oncogenic JAK3 mutations is currently unknown.
MATERIALS AND METHODS
Protein Expression and Purification
Expression: JAK3 JH2 (residues 511–790) was cloned into the
pFASTBAC1 vector (Invitrogen) with a C-terminal His6 tag and
expressed as a fusion protein in Spodoptera frugiperda (Sf 9) cells.
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For protein expression, cells were infected with 10% (v/v) virus
supernatant, grown for 48 h and collected by centrifugation.
Ni-NTA purification: Cell pellets containing JH2-His fusion
protein were resuspended in lysis buffer containing 20mM Tris-
HCl (pH 8.0), 500mM NaCl, 20% (v/v) glycerol, 0.5mM TCEP
and 20mM imidazole, supplemented with protease inhibitors
cocktail, lysed using a cell disruptor (Sonics) and clarified by
centrifugation for 1 h at 10,000 g. The supernatant was incubated
for 2 h with prewashed Ni-NTA beads (Qiagen) with gentle
rotation at 4 ◦C. The beads were extensively washed with a
buffer supplemented with 40mM imidazole, and the fusion
protein was eluted with 150mM imidazole buffer. Fractions
containing the fusion protein were pooled and buffer-exchanged
by several dilution-concentration cycles using 10KAmicon Ultra
centrifugal filters.
Size exclusion chromatography: Ni-NTA purified, buffer-
exchanged and concentrated proteins were loaded into Superdex
75 10/300 GL column (GE Healthcare Life Sciences) equilibrated
with 20mMTris-HCl (pH 8.0), 500mMNaCl, 20% (v/v) glycerol
and 0.5mM TCEP. The fractions including the protein were
collected and concentrated for further analysis.
Differential Scanning Fluorimetry
Protein concentration of 3µM was used for the measurement
of the melting temperature (Tm). Reactions were done in the
buffer used in the SEC. Addition of other components (ATP, salts)
were taken into account by including 2X buffer, if needed. Signal
arising from the fluorescent dye Life Technologies SYPROTM
Orange Protein Gel Stain, 4X working solution from 5000X
concentrate in DMSO) was measured with a conventional Real-
Time PCR system (Bio-Rad CFX), 1◦C per min from 4 to 96◦C.
Results were transferred and normalized in Microsoft Excel and
the Tm was derived from the sigmoidal function using GraphPad
Prism version 5.02 for Windows, GraphPad Software, La Jolla
California USA, https://www.graphpad.com/.
MANT-ATP Binding Assay
The steady-state fluorescence of MANT-labeled ATP was
measured as described in Mysore et al. (34). Briefly, the
fluorescently labeled MANT (2′/3′-(N-methyl-anthraniloyl)-
ATP was titrated against 1.5µM recombinant JAK3 JH2.
In addition, the protein was titrated as 0, 0.05, 0.25, 1.25,
and 6.26µM against 0.25µM MANT-ATP. FRET signal was
measured with QuantaMaster PTI Fluorometer and the data
was analyzed using GraphPad Prism version 5.02 and Microsoft
Excel. Protein titrations were done in duplicate and in MANT-
ATP titration in triplicate.
Fluorescence Polarization Assay
Fluorescence polarization measurements were performed in
black 384-well plates (ProxiPlate-384 F Plus, PerkinElmer) at
sample volume of 5µl/well on PerkinElmer Envision plate reader
using 480 nm excitation and 535 nm emission filters. Fluorescent
tracer, Bodipy FL labeled JNJ-7706621 [compound 5 in (35)] was
used at 1.5 nM concentration. Recombinant JAK1 JH2 553-836-
His, JAK2 JH2 503-827-His, JAK3 JH2 511-790-His, and TYK2
JH2 564-876-His proteins were used at concentrations (2 nM
JAK1, 150 nM JAK2, 1µM JAK3, 20 nM TYK2) dependent on
protein-tracer dissociation constants. The assays were performed
in a buffer consisting of 20mM Tris-HCl pH 8.0, 150mM
NaCl, 20% glycerol, 0.01% Brij-35, and 2mM DTT. ATP was
titrated at concentration range of 5 nM−5µM and fluorescence
polarization values obtained were fitted against log[ATP] in
GraphPad Prism to yield IC50 values. Assays were performed in
triplicate.
Plasmids and Mutagenesis
C-terminally HA-tagged full length JAK1, JAK3, and STAT5
cloned into pCIneo mammalian expression plasmid were used
for transfections.Mutations into JAK1 and JAK3were introduced
by site-directed mutagenesis using QuikChange-protocol with
specifically designed primers. The method was also used for the
domain deletion constructs.
Cell Culture, Transfection, and
Immunoblotting
JAK1 and JAK3 deficient U4C fibrosarcoma cells stably
expressing IL-2Rγ and -β receptors were kindly provided by Dr.
Claude Haan, (Life Sciences Research Unit, Signal Transduction
Laboratory, University of Luxembourg, Luxembourg, L-1511,
Luxembourg) and Hans-Günter Zerwes (Novartis Institute
for Biomedical Research). Cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum, 1% pen strep and 1% glutamine and antibiotics:
puromycin, zeozin and blasticidin for maintaining the IL-2Rγ
and -β expression.
Transient transfections were done with full-length or mutant
human JAK1-HA (75 ng), human JAK3-HA (75 ng) and
human STAT5A-HA (1.5 ng) using FuGENE HD (Promega)
according to the manufacturers’ instructions. After 34 h cells
were starved in serum-free medium overnight and stimulated
for 15min with 100 ng/ml of human IL-2. After stimulation,
cells were lysed into Triton-X cell lysis buffer and centrifuged,
and the supernatant used for SDS/PAGE and immunoblotting.
Blots were double-stained with phosphospecific antibodies (P-
Stat5 (Y694), Cell Signaling Technology and anti-phospho-JAK1
(Tyr1022/Tyr1023), Millipore) and anti-HA (Aviva Systems
Biology OAEA00009) and detected with a mix of IRDye-
labeled secondaries. The STAT5 (HA) signals were used for
normalization of phospho-STAT5 levels. Blots were quantified
using a LI-COR Odyssey CLx imaging system. A minimum
of three independent experiments were performed for each
condition.
JAK3 Homology Modeling
A JAK3 homology model was generated using the SWISS-
MODEL server with the TYK2 structure (Protein Data Bank
identification 4OLI) as the modeling template. Graphical
presentations were generated using the PyMOL Molecular
Graphics System (DeLano Scientific, San Carlos, CA).
Luciferase and Dual Luciferase Assays
STAT5 transcriptional activity was assessed by measuring
the luciferase expression (SPI Luc 2) driven by a STAT5
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responsive promoter from growth hormone regulated serine
protease inhibitor, as described previously (27). U4Cγβ cells
were transfected with indicated DNA constructs including SPI-
Luc2 and β-galactosidase reporter plasmids. The latter was
co-transfected as an internal transfection control. Transient
transfections were done in 96 well plates with FuGENE HD
(Promega) according to manufactures instructions. 42 h after
transfection, cells were stimulated (in starvation media) or
starved for 5 h after which luciferase assays were analyzed using
the dual luciferase reporter assay system (Promega) according to
manufactures instructions. Luciferase values were measured with
EnVision 2104 Multilabel Reader (Perkin Elmer). The results
are presented as relative luciferase activity (RLU) corresponding
to the firefly luciferase light emission values divided by renilla
luciferase light emission values.
In addition to Renilla luciferase (pRLTk; Promega), the β-
galactosidase reporter was also used, and similar results were
obtained with both reporters. Briefly, cells were washed twice
with PBS and 20 µl of 1X Luciferase lysis buffer was added to the
wells. 10µl of the lysate was used for luminescence measurement
with 75µl luciferase reagent. β-galactosidase signal wasmeasured
by adding 50 µl of ONPG per well and the absorbance signal
values were used for normalization of the luciferase luminescence
values.
In vivo Studies in Zebrafish
Embryos derived from jak3+/− in-crosses were injected with 100
pg/nl in vitro transcribed cappedmRNA encoding zebrafish JAK3
wild-type (WT), and M511I, I535F and M511+I535F mutants.
At 5 dpf they were fixed and subjected to whole-mount in situ
hybridization (WISH) with anti-sense rag1 probe and imaged
and quantified as described (36), with only jak3−/− embryos,
as determined by post-WISH genotyping, used in the analysis.
In other experiments, embryos from lck::GFP zebrafish were
injected and rag1 expression analyzed using RT-PCR.
RESULTS
Both JH1 and JH2 in JAK1 and JAK3 Are
Required for Functional IL-2–STAT5
Signaling
In order to investigate the functional role of JAK3 JH2 in IL-
2R signaling, we used the human fibrosarcoma U4Cγβ cell line
that stably expresses IL-2Rγ and IL-2Rβ but lacks expression
of JAK1 and JAK3 (11). A functional IL-2R signaling cascade
was reconstituted by ectopic expression of JAK1 and JAK3,
which allowed analysis of JAK1/JAK3 mutants. Optimization
of experimental conditions showed that expression of JAK1
alone induced strong basal activation of STAT5-driven luciferase
reporter SPI-Luc2 (27), which was, however, unresponsive to IL-
2 stimulation (Supplementary Figure 1A). Expression of JAK3
alone showed no basal STAT5 transcriptional activity and no
responsiveness to IL-2. IL-2-induced STAT5 activation was
achieved only by expression of both JAK1 and JAK3, which is in
line with previous studies (3, 11, 37).
Immunoblot analysis of STAT5 Y694 phosphorylation
(pSTAT5) from U4Cγβ cells transfected with JAK1 and JAK3
concurred with STAT5 transcriptional activity showing IL-2-
independent phosphorylation by JAK1 alone, lack of pSTAT5
by JAK3 alone and requirement for both JAK1 and JAK3 for
IL-2-responsiveness (Supplementary Figure 1B). Collectively
these results imply JAK1 as the immediate downstream effector
kinase and JAK3 as a regulator/activator in the IL-2R signaling
complex, thus confirming previous reports (3, 11, 37). However,
the underlying molecular mechanisms and regulatory domains
in JAK1–JAK3 heterodimer signaling are still largely unknown
and, in this context, we wanted to analyze specifically the roles of
JH2s.
In order to investigate the roles of different JH domains we
produced deletion constructs for JH1 and JH2 domains in JAK1
and JAK3 (Figure 1) In accordance with the critical role of JAK1
kinase activity in IL-2R–STAT5 signaling (see above), deletion
of JH1 in JAK1 (JAK1 1JH1) abolished both basal and IL-2-
induced pSTAT5 and STAT5 reporter activity. Similarly, deletion
of JH1 in JAK3 abolished IL-2-inducibility but retained basal
activity mediated by JAK1. Interestingly, deletion of JH2 in JAK1
also completely abrogated IL-2R signaling activity, and in JAK3
deletion of JH2 or both JH1 and JH2 prevented IL-2-inducibility
without affecting basal activity (Figures 1B,C). These results
indicate that, in addition to the kinase domains, the pseudokinase
domains in JAK1 and JAK3 are also required for IL-2R signaling.
Next, we extended our studies on the regulatory function of
JH2 to clinical JAK3 mutations. As the structure of JAK3 JH2
has not been solved, we produced a homology model based on
the TYK2 JH2-JH1 structure (Protein Data Bank (PDB) code:
4OLI, see Figure 2A) (27). We analyzed pathogenic inactivating
mutant C759R found in SCID patients as well as activating JAK3
mutants M511I and R657Q in JH2 and L857Q in JH1 (list of
mutations; see Table 1). The activating mutants are found in T-
ALL patients and reported to be constitutively active in cellular
assays and result in leukemic phenotypes in mouse models
(3). Mutations were studied in the IL-2–STAT5 pathway in
U4Cγβ cells co-expressed with wild-type JAK1. The JAK3 C759R
inhibited basal and IL-2-induced STAT5 activation as efficiently
as the kinase-inactive JAK3 JH1 mutation K855A (Figure 2B).
JAK3 M511I and R657Q showed similar, cytokine-independent
STAT5 activation as the JH1 L857Q mutant (Figures 2B,C,
Supplementary Figure 2C).
Most activating JAK3 mutants have been shown to depend
on JAK1 for signaling (3), and we sought to define the JAK1
domains required for constitutive IL-2 signaling. Activating
JAK3 mutants were transfected with either wild-type JAK1,
JAK1 1JH2 or JAK1 1JH1 into U4Cγβ cells. All tested
JAK3 mutants residing in either JH1 or JH2 were found
to depend on normal JAK1 activity and showed increased
basal STAT5 activation only in the presence of full-length
JAK1 (Figure 2B, Supplementary Figure 2A); deletion of either
JH1 or JH2 of JAK1 completely abrogated signaling as
measured by pSTAT5 and STAT5 luciferase assays (Figure 2C,
Supplementary Figures 2B,C). Taken together, these data show
that the analyzed oncogenic JAK3 JH2 and JH1mutations require
both JH1 and JH2 domains of JAK1 for constitutive signaling.
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FIGURE 1 | Both JH1 and JH2 in JAK1 and JAK3 are required for functional IL-2 signaling. (A) Schematic presentation of JAK1 and JAK3 wild-type (WT) and domain
deletion constructs. (B) Both JH1 and JH2 of JAK1 and JAK3 are required for IL-2 dependent STAT5 activation. U4Cγβ cells were transfected with JAK1 WT, JAK3
WT and domain deletion constructs together with STAT5 responsive reporter SPI-luc2 (28), either with Renilla or pRL-TK control vector (see Materials and Methods)
and starved/stimulated. Similar results were obtained with both control vectors. Data shows averages and SD from normalized values combined from three
independent experiments, each having triplicate samples. The expression of JAK1/JAK3 constructs was analyzed by anti-HA Western blotting. (C) IL-2-induced
pSTAT5 requires both JH1 and JH2 in JAK1 and JAK3. STAT5 phosphorylation and expression of JAK1, JAK3 and STAT5 were detected from cell lysates from
transfected U4Cγβ cells by immunoblotting with HA- and pTyr694 STAT5 antibodies. Similar results were obtained in three independent experiments.
Characterization of Recombinant JAK3
JH2 Shows a Domain Capable of Tight,
Cation-Independent Nucleotide Binding
Pseudokinases are generally considered to be inactive kinases but
an estimated 30–40% of pseudokinases, including JAK1, JAK2
and TYK2 JH2, bind nucleotides (21). The function of JAK3
JH2 has not been analyzed and for biochemical characterization
recombinant JAK3 JH2 (residues 511–790 with C-terminal His6-
tag) was expressed in insect cells and purified with affinity
chromatography followed by size-exclusion chromatography
(Supplementary Figures 3A,B). The protein was analyzed by
differential scanning fluorimetry (DSF) for its ability to bind
adenosine nucleotides (Figure 3A). The melting temperature
(Tm) of JAK3 JH2 (apo) was as low as 32.4 ± 0.2◦C, indicating
inherent lability of the domain but Tmwas significantly increased
by addition of ATP (1Tm 8◦C with 0.2mM ATP, 12◦C with
1mM ATP). Supplementing the buffer with either Mg2+, Mn2+
or Ca2+ (in the form of 2mM of their chloride salts) alone or
with ATP did not have a significant effect on the Tm. Adding
the monovalent cation salt KCl did not affect the Tm, which
was expected as the buffer contained monovalent NaCl. As
other JAK JH2s have been shown to require salts to bind ATP,
we tested all JAK JH2s with 500µM ATP with, or without
MgCl2 (Supplementary Figure 4A) and confirmed, that the Tm
of JAK1, JAK2 and TYK2 JH2s increase only if MgCl2 is added
with ATP, while JAK3 JH2 has higher 1Tm without Mg2+ (ATP
only). The cation-independency of ATP binding was confirmed
by adding 2mM of the chelating agent EDTA to the buffer, which
did not affect the Tm for JAK3 JH2 ATP (Figure 3B).
Measuring the affinity of JAK3 JH2 binding to the fluorescent
ATP-analog MANT [2
′
-(3
′
)-O-(N-methylanthraniloyl)]-ATP
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FIGURE 2 | Mutations in JAK3 JH2 can alter the function of the IL-2 pathway. (A) Localizations of the JAK3 mutants used in this article. Homology model of JAK3
JH2-JH1 (based on the TYK2 structure in Protein Data Bank (PDB) code: 4OLI) and the JAK3 JH1 structure [PDB code: 1YVJ (38)] were aligned with the JH1-JH2
structure of TYK2 (PDB code: 4OLI). JH2 is shown in red and JH1 in gray. Close-ups of the mutations are shown in subpanels. C759 is shown in the main picture. In
the lower left panel, the (possible) interaction pair R657–D864 (in JH1) is shown. In the right panel, ATP was aligned from ATP-bound form of PKA [PDB code: 1ATP
(39)]. (B) JAK3 JH2 C759R mutation efficiently inhibits IL-2 signaling and activating mutations in JAK3 JH2 and JH1. Luciferase assay of STAT5 activation in U4Cγβ
cells transfected with JAK1 WT and JAK3 point mutations, SPI-luc2 reporter and β-galactosidase control. Values were normalized to JAK1 WT and JAK3 WT
transfected sample Errors bars show SD of triplicate samples. Similar results were obtained using pRL-TK as a control. (C) Activating JAK3 mutants rely on both JH1
and JH2 of JAK1 for constitutive downstream signaling. SPI-luc2 reporter was used to detect the activation of STAT5 in U4Cγβ cells. Cells were transfected with WT
or domain deletion JAK1 and WT or constitutively active JAK3 mutants. β-galactosidase plasmid was used as an internal control for the transfection efficiency. Values
were normalized to WT JAK1 and JAK3. Error bars are SD of triplicate samples.
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TABLE 1 | Mutations used in this study.
JAK Mutation Domain Effect References
JAK3 M511I JH2 Found in T-ALL patients, constitutively active (3)
R657Q JH2 Found in T-ALL patients, constitutively active (3)
L857Q JH1 Found in T-ALL patients, constitutively active (3)
C759R JH2 Found in SCID patients, inhibits JAK3 kinase activity and reduces STAT5
activity
(31)
K855A JH1 Catalytic lysine, kinase dead
K566A JH2 Homologous to K855A, disrupts ATP binding to JH2
I535F JH2 Homologous to JAK2 I559F, disrupts ATP binding to JH2 (24)
JAK1 V658F JH2 Homologous to JAK2 V617F, constitutively active (17)
I535F JH2 Homologous to JAK2 I559F, disrupts ATP binding to JH2 (24)
FIGURE 3 | Nucleotide binding to recombinant JAK3 JH2. (A) JAK3 JH2 binds ATP without cations. The effect of ATP on Tm of JAK3 JH2 is shown in the left panel.
The following graph shows changes in the melting temperature (1Tm) in JAK3 JH2 in the presence of different cations and ATP. (B) Chelating agent does not affect
ATP-induced increase on Tm of JAK3 JH2. DSF analysis performed in the presence of ATP (1mM) and chelating agent EDTA (2mM). (C) MANT-ATP binding assay
with recombinant JAK3 JH2. Both protein and MANT-ATP were titrated and both experiments gave similar Kd in the sub-micromolar range. Left panel: titrating
MANT-ATP to 1.5µM JAK3-JH2. Kd range 330–440 nM. Right panel: titrating JAK3 JH2 to 0.25µM MANT-ATP, Kd 500 nM. Protein concentrations were 0; 0.05;
0.25; 1.25 and 6.25µM. In both figures, the Y-axis is the fraction of ligand-bound protein in relation to the total protein amount ([PL/Ptot]). The MANT-ATP titration was
repeated three times and all experiments are plotted in the lower left panel. Protein titration was repeated twice and both experiments are blotted in the figure.
showed that JAK3 JH2 binds MANT-ATP with a dissociation
constant (Kd) of 0.4µM (Figure 3C). Similar values were
obtained by titration of the ligand to a constant amount of
protein and vice versa. IC50 values was determined using
fluorescent polarization assay (FP), by competition assay,
where ATP competes with ATP pocket binding tracer. The
IC50 values for JAK JH2s were compared, and the IC 50 for
JAK3 JH2 was 16µM (without MgCl2), indicating tighter
ATP-binding affinity for JAK3 JH2 compared to other JAK
JH2s (Supplementary Figure 4B, Table 2). Approximation
of the JAK3 JH2 Kd was further with DSF, where 50
nM−1mM ATP was titrated to 3µM protein. The value
was higher than measured with MANT-ATP, namely 40.4 ±
97.1µM (Supplementary Figure 4C). However, the variation
was wide and, as there was no saturation seen when the
values were fitted, no Kd was obtained for other JAK JH2s
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(Supplementary Figure 4C). The differences in the magnitude
of the Kd and IC50 values stems from the methods used to
evaluate the affinity, e.g., the fact that MANT-ATP uses modified
ATP that may affect the binding properties of the molecule.
However, both the MANT-ATP and FP methods showed that
JAK3 JH2 binds ATP tighter compared to other JAK JH2s, and
the binding is cation-independent. Furthermore, the effect of
ATP binding to the stability of JAK3 JH2 was greater compared
to other JAK JH2s (Supplementary Figure 4C, Table 2).
Finally, we investigated the binding of ADP and AMP
to JAK3 JH2 (Supplementary Figure 4D). ADP showed a
significantly reduced 1Tm compared to ATP, and AMP showed
no effect on Tm indicating that JAK3 JH2 does not bind AMP
and prefers ATP over its de-phosphorylated counterparts. An
autophosphorylation assay with radiolabeled ATP did not show
incorporation of 32P into JAK3 JH2, suggesting that JAK3 JH2
does not possess catalytic activity (Supplementary Figure 4E).
Mutating the JAK3 JH2 ATP-Binding Site
Reverts the Oncogenic JAK3
Hyperactivation
Given that JAK3 JH2 has a functional nucleotide-binding site, we
wanted to analyze the functional role of ATP binding to JAK3 JH2
in IL-2 signaling. The JAK3 JH2 model identified two residues
in the ATP-binding pocket conserved between JAKs (Figure 2A)
and suited for mutagenesis.We thusmutated I535 in the β2-sheet
of the JH2 N-lobe to a bulkier phenylalanine to sterically inhibit
ATP binding. The corresponding JAK2 mutation (JAK2 I559F)
has been shown to inhibit ATP binding without affecting the
stability of JAK2 JH2 (24). We also mutated the conserved JAK3
JH2 β3 lysine K556, to alanine. The activities of the mutant JAK3
were analyzed in U4Cγβ cells with STAT5-responsive reporter
and pSTAT5 analysis. Neither mutation disrupted responsiveness
to IL-2 stimulation and the signaling properties resembled wild-
type JAK3 (Figure 4).
Inhibition of ATP binding to JH2 by mutations or small
molecular weight (smw) inhibitors has been demonstrated to
abrogate pathogenic hyperactivation of JAK2 and cytokine
signaling via TYK2, respectively (23, 24). To assess the effect
of JH2 nucleotide binding in constitutively active JAK3, we
constructed double mutants consisting of an activating mutant
(M511I, R657Q, or L857Q; see Figure 2) and either of the
ATP binding mutants (I535F or K556A). The constructs were
transiently transfected and analyzed for STAT5 activation (SPI-
luc2 reporter) and pSTAT5 (immunoblotting) (Figures 4A,B,D,
Supplementary Figure 5A). In both assays the JH2 ATP-binding
site mutations reduced STAT5 activation back to or below wild-
type JAK3 levels while retaining cytokine-responsiveness. The
sole exception was JAK3 L857Q+K556A, which showed strongly
reduced activation by cytokine as well. The more conservative
sterically hindering ATP-binding site mutation I535F, however,
resulted in wild-type-like STAT5 activation in the L857Q context.
IL-2-responsiveness was also regained in M511I+I535F/K556A
and R657Q+I535F/K556A (Figures 4A,B). Notably, these results
are distinct from complete removal of JAK3 JH2 (1JH2, see
Figure 1) or removal of JH1 kinase activity by the JAK3 JH1
β3 lysine-to-alanine mutation JAK3 K855A, which resulted in
unresponsiveness to cytokine, even when combined with the
activating M511I mutation (Figure 4D).
In order to investigate the mechanism of suppression in
JAK3 oncogenic signaling by the JH2 ATP-binding mutants, we
analyzed phosphorylation of the JAK1 activation loop tyrosine
residues. The JH2ATP bindingmutation in JAK3 doublemutants
reduced JAK1 activation loop phosphorylation compared to
activating mutations alone (Supplementary Figure 5C).
The effect of JH2 ATP binding on JAK3 oncogenic
mutants was also analyzed using zebrafish (Danio rerio).
Expression of rag1, an IL-2Rγc/JAK3-dependent marker for
mature lymphoid cells, was analyzed in JAK3-deficient embryos
injected with mRNA encoding JAK3 WT, M511I, I535F or
the combined M511I + I535F mutant mRNA as described
(36). Each produced a range of rag1 expression, but both
M511I and I535F elicited a small but reproducible enhancement
in the mean rag1 expression compared to WT, which was
significantly reduced in the ATP binding deficient M511I
+ I535F double mutant (Supplementary Figure 6). A similar
reduction in rag1 expression was observed with the double
mutant compared to M511I in qPCR experiments performed
on embryos from transgenic lck::GFP zebrafish injected with
JAK3 WT, M511I and M511I + I535F mRNA (data not
shown). In contrast, the presence of the I535F mutation
did not ablate the induction of rag1 expression by JAK3
WT in either case (Supplementary Figure 6 and data not
shown).
Together, the data indicate that disrupting ATP binding
to JAK3 JH2 preserves IL-2-responsiveness but decreases
constitutive STAT5 activation, probably by reducing the
activating potential of JAK3 to JAK1.
JAK3 JH2 ATP-Binding Mutations Do Not
Inhibit Activation by Pathogenic JAK1
Mutations
We have previously shown that JH2 ATP-binding mutations
suppress activating mutations in homomeric cytokine receptor
signaling in the same JAK molecule (24). Using the IL-2–
JAK1/JAK3 signaling system, we wanted to study the effect of
JH2 ATP binding in heterodimeric JAK signaling by assessing
whether inhibition of ATP binding in one JAK JH2 could
suppress activation by hyperactivating mutations in the other
JAK in trans. We co-transfected JAK1 JH2 ATP mutant
I597F (corresponding to JAK3 I535F) with JAK3 activating
mutation M511I, or JAK3 JH2 I535F mutant with the activating
JAK1 T-ALL-associated mutation V658F (analogous to the
most prevalent MPN-inducing JAK2 mutation V617F) (40).
Similar amounts of wild-type and mutated JAK3 and JAK1
proteins were expressed as quantified by western blotting
(Supplementary Figure 5B).
JAK1 JH2 mutant I597F, when co-transfected with JAK3
M511I, did not reduce (hyper)activation and thus did not restore
cytokine responsiveness (Figure 5A). In the reverse experimental
setting, the JH2 ATP pocket mutation JAK3 I535F could not
reduce the activation of constitutively active JAK1 V658F.
Together these data suggest that JH2 ATP-site mutations exert
their direct suppressing function in cis and cannot suppress
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FIGURE 4 | Inhibition of ATP binding to the pseudokinase domain of JAK3 reverts pathogenic, ligand-independent JAK3 signaling, while retaining
cytokine-responsiveness. (A) JAK3 JH2 ATP-binding site mutations suppress activating JAK3 mutants. Luciferase assay was performed in U4Cγβ cells transfected
with JAK1 and the indicated JAK3 mutants using β-galactosidase as a transfection control. The results are from three independent experiment, each having triplicate
samples (n = 9, expect for K556A n = 7). Similar results were obtained with pRL-TK control. Data is normalized to the basal wild-type sample, errors are presented as
SD. Statistical analysis of the activating mutations, and their corresponding double mutants were done with two-tailed t-test using unequal variances. **p < 0.001.
(B) Representative Western blot of the transiently transfected U4Cγβ cell lysates showing the pSTAT5 signal. HA-tagged STAT5 was co-transfected with HA-tagged
JAK1 and JAK3 and the lysates were blotted with anti-HA and anti-pSTAT5. Lower panel: Quantitative pSTAT5/STAT5 signal analysis. Activation of JAK3 signaling by
M511I, R657Q and L857Q is significant (*p < 0.05). Data is average of five experiments. (C) The localization of the mutated JAK3 JH2 ATP-binding residues.
Homology model of JAK3 JH2 (based on TYK2 structure from PDB, code: 4OLI), ATP is shown in gray. (D) Kinase-inactive JAK3 K855A abolishes IL-2 signaling in the
presence of the activating JAK3 mutation M511I. Luciferase assay with STAT5-responsive promoter and with pRL-TK control.
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TABLE 2 | Comparison of JAK JH2s.
JAK JH2 Phospho
transfer
activity
Kd (MANT-ATP)*
(References)
[µM]
IC50(FP)*
[µM]
TmApo
[◦C]
TmATP
[◦C]
1Tm
(1mM ATP)
[◦C]
Cations
JAK2 Weak 1.3 (24) 102 43 46 4.9 Yes
JAK1 No 3.1 (24) 110 46 3.9 Yes
TYK2 No 15 (23) 471 48 48 0.9 Yes
JAK3 No 0.5 16 32 41 9.9 No
*Kd (MANT-ATP) and IC50 values are shown with MgCl2 for JAK1, JAK2 and TYK2 and no MgCl2 added for JAK3 JH2.
activation caused by mutations in the other JAK of a heteromeric
JAK pair. Mutants disrupting the JH2 ATP-binding possibly
function by lowering the kinase activity of JH1 though lowering
the stability of the JH2 αC, which interacts with JH1 (24, 32).
To further investigate JAK1–JAK3 interplay on IL-2R, we
analyzed the loss-of-function JAK3 SCID mutant C759R (see
Figure 2A). The JAK3 C759R mutation completely abrogated
signaling of wild-type JAK1 but still failed to inhibit signaling
by the hyperactive JAK1 V658F (Figure 5B). Comparable
JAK1 and JAK3 expression levels between the mutants and
wild-type were confirmed by immunoblotting the samples
(Supplementary Figure 5B).
DISCUSSION
Although JAKs have been intensively studied since their
discovery in the late 1980s and early 1990s, many of their
molecular regulatory mechanisms are still not fully understood.
This notion is particularly true for JAK3, which has nonetheless
become a relevant drug target. Importantly, critical information
of its regulation is lacking, and for example, structural data
exists only for the JAK3 JH1 domain (41). In this study, we
focused on characterization of JAK3 JH2 and its function in
the context of both normal IL-2R signaling and oncogenic
signaling mediated via activating JAK3mutations. We found that
in addition to the well-established functions of the respective
JH1s, the JH2s of JAK3 and JAK1 are also required for
IL-2 signaling and for hyperactivation of JAK1 and JAK3
oncogenic mutants. Biochemical analysis of recombinant JAK3
JH2 showed that the domain binds ATP but differs from
other JAK JH2s in terms of a lower initial Tm, more
robust stabilizing effect by ATP, and cation-independency of
the nucleotide binding. Furthermore, our cellular signaling
analysis suggests that disrupting the ATP-binding site of JAK3
JH2 can inhibit activation caused by JAK3 gain-of-function
mutations.
Our DSF results indicate that JAK3 JH2 binds ATP in a cation-
independent manner. In canonical protein kinases such as PKA,
Mg-ATP binds in the cleft between the N and C lobes and
the two Mg2+ ions are coordinated by an aspartic acid in the
conserved DFG motif (21). However, pseudokinases are known
to possess non-canonical nucleotide binding modes and JAK2
and TYK2 JH2s bind ATP with a single cation coordinated by
an upstream asparagine (N678 in JAK2 JH2) (19). Interestingly,
this asparagine is conserved also in JAK1, JAK2 and TYK2 JH2s,
as well as in the zebrafish (danio rerio) JAK3, but is replaced
by a positively charged lysine (K652) in JAK3 JH2 (Figure 6).
This difference can explain the cation-independency of ATP
binding in JAK3 as it would replace the need for a positively
charged cation in coordinating the negatively charged phosphates
of ATP. A few other pseudokinases with cation-independent
ATP-binding modes have been characterized (19, 21). Of
these, MLKL, STRADα, and EphB6 are catalytically inactive,
while CASK has been reported to possess phosphotransfer
activity (21, 42). Furthermore, ULK4 has been shown to bind
nucleotides without cations, but its kinase activity has not
been characterized (21). MLKL, STRADα, EphB6 and CASK
have divergent sequences in place of the conventional cation-
binding DFGmotif, namely GFE, GLR, RLG, GFG (all conserved
between human and mouse), respectively. In all JAK JH2s,
this motif is DPG. In addition, the residue corresponding to
JAK3K652 varies between the above-mentioned proteins: human
MLKL has conserved the typical Asn, while ULK4 has a Lys
residue similar to JAK3 JH2 and CASK, EphB6 and STRADα
all have different residues (Cys, Ser and His, respectively,
see Figure 6). These examples illustrate the highly divergent
mechanisms for ATP binding that have evolved in pseudokinases
(19, 21).
Characterization of recombinant JAK3 JH2 showed an
unstable protein with low Tm, but 3-, 6- and 30-fold tighter
MANT-ATP binding compared to JAK2, JAK1, and TYK2 JH2s,
respectively. A similar trend was also seen in IC50 values derived
from a fluorescence polarization competition assay in which
a fluorescently-labeled small molecule probe is competed off
with unlabeled ATP. In addition, the effect of ATP on the
protein stability was considerably larger in JAK3 than in other
JAKs (Table 2). Based on the high ATP-binding affinity and
lack of kinase activity in JAK3 JH2 (Supplementary Figure 4E),
we speculate that ATP binding has a mostly structural role in
JAK3 JH2. Furthermore, failure to produce recombinant JAK3
JH2 with mutations designed to disrupt ATP binding (and the
success in production of the JAK3 JH2 with the activating R657Q
mutation) also indirectly support the notion of a stabilizing effect
for ATP (Supplementary Figure 3C).
To assess the effects of ATP binding to JAK3 JH2 on
cellular signaling, we constructed mutations into the JH2 ATP
binding pocket of full-length JAK3 targeting residues I535 and
K556 (see Figures 2, 4). JAK3 JH2 ATP-binding site mutations
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FIGURE 5 | Disrupting the JAK3 JH2 nucleotide binding site inhibits JAK3-induced, but not JAK1-induced, hyperactivation, and vice versa. (A) Constitutive activation
of STAT5 caused by oncogenic JAK3 mutations are suppressed only by ATP-binding site mutations in JAK3 and not its dimerization partner JAK1. Luciferase assay of
U4Cγβ cells transiently transfected with JAK1, JAK3, SPI-luc2 and pRL-TK. Results are average from two separate experiments each with triplicate or duplicate
(I597F+I535F and I597F+WT JAK3) samples. The results are normalized to the JAK1 WT and JAK3 WT sample. Error bars show the SD. (B) Inhibitory JAK3 SCID
mutation C759R does not reduce oncogenic hyperaction of JAK1-mutant. Luciferase assay in U4Cγβ cells transiently transfected with JAK1, JAK3, SPI-luc2, and
pRL-TK. Error bars are SD of triplicate samples and the data is representative of three independent experiments. Supplementary Figure 5B shows immunoblotting
for protein expression levels.
FIGURE 6 | Left: Homology model of JAK3 JH2 aligned with the crystal structure of JAK2 [PDB code: 4FVQ (25)]. JAK3 is shown in red and JAK2 in orange. ATP is
shown as black shits and the Mg2+ present in the JAK2 JH2 structure as a green sphere. Right: An alignment of human and mice sequences of JAKs and several
other pseudokinases for Mg2+ coordination, JAK3 K652, which is conserved as N in other JAKs, and is important for Mg2+ coordination, is highlighted. Also the
canonical DFG motif are compared and show variation between the pseudokinases.
efficiently suppressed ligand-independent STAT5 activation by
JAK3 ALL-mutants R657Q, M511I in JH2, as well as L857Q in
JH1 (Figure 4). The suppressing effect of the I535F mutant was
further studied in the zebrafish model, where the double mutant
(M511I+ I535F) induced lower rag1 expression compared to the
M511I mutant (Supplementary Figure 6 and data not shown).
In contrast to the kinase-inactive form of JAK3 (K855A), which
lowered both ligand-independent basal activity and IL-2 induced
signaling, the JH2 ATP-binding site mutations only suppressed
ligand-independent STAT5 activation, while retaining IL-2-
dependent STAT5 activation. The only exception to this was
the double mutant L857Q + K556A, which showed lowered
signaling capacity for as of yet unknown reasons.
Based on homology modeling the JAK3 JH2 gain-of-function
mutations R657Q and M511I reside in the autoinhibitory JH1–
JH2 interface (see Figure 2 for suggested JH2–JH1 interaction
pair between JAK3 R657 and D865), which, when disrupted, is
likely to cause increased JAK3 JH1 basal tyrosine kinase activity
(27, 32). This, in turn activates JAK1, which finally acts as the
effector kinase phosphorylating STAT5 (3, 43) and leading to
ligand-independent activation of the IL-2-STAT5 pathway. Our
results presented here corroborate this hypothesis as we show
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that functionally sound JAK1 (including both JH1 and JH2) is
required for STAT5 activation also by clinical gain-of-function
JAK3 mutations (3, 43).
In contrast to the JH2 mutations, the L857Q, which is located
next to the catalytically important K855 in JH1 (see Figure 2) and
thus unlikely to disrupt the JH1–JH2 interaction, might activate
JH1 more directly by e.g., repositioning the JH1 C-helix or the
nearby DFG motif into a more active conformation. Our data
shows that L857Q is still dependent on JAK1 JH1/JH2, thus
the mutation does not seem to result in sufficiently high JAK3
JH1 kinase activity to lead to JAK1-independent phosphorylation
of STAT5 as has been suggested for a proline-mutation of the
same residue: L857P (43). Interestingly, our results also show that
L857Q is suppressed by JAK3 JH2 ATP-binding site mutations,
thus showing clear commonalities in activation mechanisms of
JAK3 JH2 and JH1-borne gain-of-function mutations. Molecular
dynamics simulations of JAK2 JH2 have suggested that ATP
binding stabilizes the N lobe of C helix (αC) in JH2 (24), and
this is likely to be the case for JAK3 as well. Whether this
stabilization causes strengthening of the JH2-JH1 interaction
(and thus suppression of gain-of-functionmutations), or whether
ATP binding to JH2 stabilizes a conformation of JH2 that
enables a distinct activating interaction involved in ligand-
independent activation of JAKs, is currently not unequivocally
solved (24).
In addition to activating JAK3 mutations, we studied the
SCID-related loss-of-function mutation JAK3 C759R. JAK3
C759R has been shown to be deficient in phosphorylating
STAT5 and STAT3 and lacks kinase activity, but to be
constitutively phosphorylated on the JH1 activation loop (JAK3
Y980-981) and bind to its receptor IL-2Rγ (31). JAK3 JH2
homology modeling suggests that mutation of C759 on α-
helix H (see Figure 2C) to the bulkier and cationic Arg is
likely to cause severe disruption of the JH2 C-lobe. Indeed,
JAK3 C759R showed strongly reduced STAT5 activation and
the effect was comparable to JAK3 1JH2 or kinase-dead JAK3
K855A.
Currently it is not clear, whether inhibition of JH1 by
JH2 occurs in cis or trans in physiological JAK dimers,
and data supporting both hypotheses has been presented (9).
However, the interplay between JAK1 and JAK3 is evident in
hematological malignancies, and cells transformed by activating
JAK1 mutations become resistant to JAK inhibitors by acquiring
activating mutations in JAK3 and vice versa (44). Considering
the tight JAK1–JAK3 interplay on IL-2R, we studied the possible
cross-regulation between JAK1 and JAK3 JH2s and observed
that mutating the JAK1 JH2 ATP binding site could not
inhibit activation caused by JAK3 M511I, which was also the
case in the reversed experimental setting (JAK3 JH2 ATP-
site mutant transfected with constitutively active JAK1 V658F).
These data suggest that any suppressing effect caused by
disrupting the JAK3 JH2 ATP-binding site is exerted only in
cis and not between JAK3 and JAK1. However, as noted before,
JAK1 is the dominant effector in STAT5 activation, and thus
the overexpression of JAK1 in our experimental setup may
compensate for any inhibitory effects of a JAK3 JH2 ATP
binding mutant. Furthermore, in our experimental approaches
we have used rational mutagenesis and deletion/recombinant
constructs, and although the constructs have been designed
based on best available information they are not natural
proteins and thus our experimental systems bear inherent
limitations.
We also tested the JAK1–JAK3 interaction by co-transfecting
the inhibitory JAK3 SCID mutant C759R with JAK1 V658F.
Again, JAK1 dominancy was apparent and JAK3 C759R could
not reduce the activation of constitutively active JAK1 V658F
even though it did inhibit IL-2-induced activation of wild-
type JAK1. Together, these data support a model in which
JAK3 acts as a regulating initiator kinase mainly responsible
for activation of JAK1, which subsequently phosphorylates
downstream targets. If JAK1 is activated by other means,
like constitutively activating JAK1 mutations, any activating
functions of JAK3 become unnecessary. Notably, the reverse is
not true and even mutationally activated JAK3 relies on JAK1 for
effector functions.
The vast majority of JAK inhibitors currently in use or
development target the kinase domain of JAKs in its active,
DFG-in, conformation, and they often suffer from poor
selectivity (45). Novel JAK3 inhibitors have been developed
that bind to a JAK3-specific, non-catalytic cysteine (C909) in
the JH1 domain, thus enabling significant selectivity toward
JAK3 (41, 46). Recently, an ATP binding competitive inhibitor
against JH2 of TYK2 was shown to have high specificity
and efficacy in IL-23 and type I IFN signaling (47). Our
results suggest that the JAK3 JH2 ATP pocket may also
be a relevant therapeutic target in diseases caused by JAK3
hyperactivation.
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